P0021
Pantoprazole sodium hydrate
≥98% (HPLC)
别名:
5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt hydrate, Pantozol hydrate, Protonix hydrate
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C16H14F2N3O4S · Na · xH2O
CAS号:
分子量:
405.35 (anhydrous basis)
分類程式碼代碼:
12352203
PubChem物質ID:
NACRES:
NA.77
推荐产品
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
技術
HPLC: suitable
gas chromatography (GC): suitable
顏色
white to off-white
溶解度
H2O: ≥20 mg/mL
起源
Novartis
儲存溫度
−20°C
SMILES 字串
O.[Na+].COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[n-]2)c1OC
InChI
1S/C16H14F2N3O4S.Na.H2O/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;;/h3-7,15H,8H2,1-2H3;;1H2/q-1;+1;
InChI 密鑰
CGJRLPRCWSHOFU-UHFFFAOYSA-N
基因資訊
human ... ATP4A(495) , ATP4B(496)
應用
Pantoprazole sodium hydrate has been used:
- as a standard in high-performance liquid chromatography (HPLC){58
- as a prazole to study its effects on prodrug activation and human immunodeficiency virus 1 (HIV-1) inhibition
- to study its effects on breast cancer resistance protein (BCRP) inhibitors in various in vitro membrane preparations from various cell lines
生化／生理作用
Pantoprazole has the potential to treat symptoms of heartburn and acid regurgitation. It also has been studied to treat Helicobacter pylori infection and duodenal ulcer.
Pantoprazole is a benzimidazole derivative,activated in acidic environment. It is useful in treating long term prophylaxis and acid-related disorders.
Pantoprazole is a gastric proton pump inhibitor.
特點和優勢
This compound is featured on the Acid-Sensing (Proton-gated) Ion Channels (ASICs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
A Fitton et al.
Drugs, 51(3), 460-482 (1996-03-01)
Pantoprazole is an irreversible proton pump inhibitor which, at the therapeutic dose of 40mg, effectively reduces gastric acid secretion. In controlled clinical trials, pantoprazole (40mg once daily) has proved superior to ranitidine (300mg once daily or 150mg twice daily) and
Analysis of ibuprofen, pantoprazole, and itopride combination therapeutic drugs in human plasma by solid phase membrane microtip extraction and high-performance liquid chromatography methods using new generation core shell C18 column
Ali I, et al.
Journal of Liquid Chromatography and Related Technologies, 39(7), 339-345 (2016)
Pantoprazole
<BIG>Perry CM and Ibbotson T</BIG>
Drugs, 101-132 (2003)
Khamushavalli Geeviman et al.
Cellular and molecular neurobiology, 38(8), 1491-1504 (2018-10-12)
Gastric H+/K+-ATPase or vacuolar-ATPases (V-ATPases) are critical for the cancer cells survival and growth in the ischemic microenvironment by extruding protons from the cell. The drugs which inhibit V-ATPases are known as proton pump inhibitors (PPIs). In the present study
<BIG>Rissling O</BIG>
Interaction of Mycophenolic Acid and Pantoprazole: A Pharmacokinetic Crossover Study (2017)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门